Publicaciones en las que colabora con JOSE ANGEL RUIZ ORTEGA (38)

2020

  1. Changes in Day/Night Activity in the 6-OHDA-Induced Experimental Model of Parkinson’s Disease: Exploring Prodromal Biomarkers

    Frontiers in Neuroscience, Vol. 14

2019

  1. Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats

    Experimental Neurology, Vol. 322

2018

  1. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)

    Molecular Neurobiology

  2. Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212

  3. Nanodelivery of cerebrolysin and rearing in enriched environment induce neuroprotective effects in a preclinical rat model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 286-299

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

2016

  1. Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors

    Experimental Neurology, Vol. 277, pp. 35-45

  2. Cannabinoids and Motor Control of the Basal Ganglia: Therapeutic Potential in Movement Disorders

    CANNABINOIDS IN HEALTH AND DISEASE (INTECH EUROPE), pp. 59-92

  3. Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats

    Neurobiology of Disease, Vol. 89, pp. 88-100

  4. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230

2015

  1. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858

2014

  1. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in l-DOPA-treated rats

    Neuropharmacology, Vol. 79, pp. 726-737

  2. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease

    International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687

  3. Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson's disease

    Frontiers in Neural Circuits, Vol. 8, Núm. MAR

  4. Modulation of the subthalamic nucleus activity by serotonergic agents and fluoxetine administration

    Psychopharmacology, Vol. 231, Núm. 9, pp. 1913-1924

2013

  1. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190

2012

  1. Endocannabinoid modulation of dopaminergic motor circuits

    Frontiers in Pharmacology, Vol. 3 JUN

  2. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats

    PLoS ONE, Vol. 7, Núm. 8

2011

  1. Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats

    Psychopharmacology, Vol. 214, Núm. 2, pp. 379-389

2010

  1. Regulation of subthalamic neuron activity by endocannabinoids

    Synapse, Vol. 64, Núm. 9, pp. 682-698